-
1
-
-
69949102133
-
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
-
Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M., Racine-Poon, A. (2009). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 28:1445-1463.
-
(2009)
Statistics in Medicine
, vol.28
, pp. 1445-1463
-
-
Brannath, W.1
Zuber, E.2
Branson, M.3
Bretz, F.4
Gallo, P.5
Posch, M.6
Racine-Poon, A.7
-
2
-
-
84891812279
-
-
Brilinta label. Available at
-
Brilinta label. (2013). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2013/022433s006lbl.pdf
-
(2013)
-
-
-
3
-
-
1842453957
-
Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; Power and sample size for the interaction test
-
Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 57:229-236.
-
(2004)
Journal of Clinical Epidemiology
, vol.57
, pp. 229-236
-
-
Brookes, S.T.1
Whitely, E.2
Egger, M.3
Smith, G.D.4
Mulheran, P.A.5
Peters, T.J.6
-
4
-
-
0036293346
-
-
Cold comfort
-
Cold comfort. (2002). Lancet Infectious Diseases 2:385.
-
(2002)
Lancet Infectious Diseases
, vol.2
, pp. 385
-
-
-
5
-
-
0036431372
-
Issues related to subgroup analysis in clinical trials
-
Cui, L., Hung, H. M., Wang, S. J., Tsong, Y. (2002). Issues related to subgroup analysis in clinical trials. Journal of Biopharmaceutical Statistics 12:347-358.
-
(2002)
Journal of Biopharmaceutical Statistics
, vol.12
, pp. 347-358
-
-
Cui, L.1
Hung, H.M.2
Wang, S.J.3
Tsong, Y.4
-
6
-
-
84891770167
-
-
Diovan label. Available at
-
Diovan label. (2002). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2002/20665s16lbl.pdf
-
(2001)
-
-
-
7
-
-
84891797487
-
-
Erbitux label. Available at
-
Erbitux label. (2012). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2012/125084s225lbl.pdf
-
(2012)
-
-
-
8
-
-
84891799670
-
-
Food and Drug Administration. Available at
-
Food and Drug Administration. (2013). Health Human Services, Code of Federal Regulation, 21CFR314.126. Available at: http://www.accessdata.fda.gov/ scripts/ cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=314.126
-
(2013)
Health Human Services, Code of Federal Regulation, 21CFR314.126
-
-
-
11
-
-
27744537954
-
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
-
Freidlin, B., Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11:7872-7878.
-
(2005)
Clinical Cancer Research
, vol.11
, pp. 7872-7878
-
-
Freidlin, B.1
Simon, R.2
-
12
-
-
84861631414
-
Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage
-
Gregson, B. A., Broderick, J. P., Auer, L. M., Batjer, H., Chen, X. C., Juvela, S., Morgenstern, L. B., Pantazis, G. C., Teernstra, O. P. M., Wang, W. Z., Zuccarello, M., Mendelow, A. D. (2012). Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage. Stroke 43:1496-1504.
-
(2012)
Stroke
, vol.43
, pp. 1496-1504
-
-
Gregson, B.A.1
Broderick, J.P.2
Auer, L.M.3
Batjer, H.4
Chen, X.C.5
Juvela, S.6
Morgenstern, L.B.7
Pantazis, G.C.8
Teernstra, O.P.M.9
Wang, W.Z.10
Zuccarello, M.11
Mendelow, A.D.12
-
13
-
-
46449103363
-
PREDICT-1: The first powered prospective trial of pharmacogenetic screening to reduce drug adverse events
-
CNA106030 Study team
-
Hughes, S., Hughes, A., Brothers, C., Spreen, W., Thorborn, D., CNA106030 Study team. (2008). PREDICT-1: The first powered prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharmaceutical Statistics 7:121-129.
-
(2008)
Pharmaceutical Statistics
, vol.7
, pp. 121-129
-
-
Hughes, S.1
Hughes, A.2
Brothers, C.3
Spreen, W.4
Thorborn, D.5
-
14
-
-
77957340034
-
Consideration of regional difference in design and analysis of multi-regional trials
-
Hung, H. M. J., Wang, S. J., O'Neill, R. (2010). Consideration of regional difference in design and analysis of multi-regional trials. Pharmaceutical Statistics 9:173-178.
-
(2010)
Pharmaceutical Statistics
, vol.9
, pp. 173-178
-
-
Hung, H.M.J.1
Wang, S.J.2
O'neill, R.3
-
17
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., Press, M. F., Malzman, J., Florance, A., O'Rourke, L., Oliva, C., Stein, S., Pegram, M. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology 27(33):5538-5546.
-
(2009)
Journal of Clinical Oncology
, vol.27
, Issue.33
, pp. 5538-5546
-
-
Johnston, S.1
Pippen, J.2
Pivot, X.3
Lichinitser, M.4
Sadeghi, S.5
Dieras, V.6
Gomez, H.L.7
Romieu, G.8
Manikhas, A.9
Kennedy, M.J.10
Press, M.F.11
Malzman, J.12
Florance, A.13
O'rourke, L.14
Oliva, C.15
Stein, S.16
Pegram, M.17
-
18
-
-
0034831901
-
Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure
-
Highlights of the scientific sessions of the American College of Cardiology, 2001
-
Louis, A., Cleland, J. G. F., Crabbe, S., Ford, S., Thackray, S., Houghton, T., Clark, A. (2001). Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001. European Journal of Heart Failure 3:381-387.
-
(2001)
European Journal of Heart Failure
, vol.3
, pp. 381-387
-
-
Louis, A.1
Cleland, J.G.F.2
Crabbe, S.3
Ford, S.4
Thackray, S.5
Houghton, T.6
Clark, A.7
-
19
-
-
20444502136
-
Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: The role of levofloxacin 750 mg
-
Martinez, F. J., Grossman, R. F., Zadeikis, N., Fisher, A. C., Walker, K., Ambruzs, M. E., Tennenberg, A. M. (2005). Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: The role of levofloxacin 750 mg. European Respiratory Journal 25:1001-1009.
-
(2005)
European Respiratory Journal
, vol.25
, pp. 1001-1009
-
-
Martinez, F.J.1
Grossman, R.F.2
Zadeikis, N.3
Fisher, A.C.4
Walker, K.5
Ambruzs, M.E.6
Tennenberg, A.M.7
-
20
-
-
61349150491
-
Optimizing trial design: Sequential, adaptive, and enrichment strategies
-
Mehta, C., Gao, P., Bhatt, D. L., Harrington, R. A., Skerjanec, S., Ware, J. H. (2009). Optimizing trial design: Sequential, adaptive, and enrichment strategies. Circulation 119:597-605.
-
(2009)
Circulation
, vol.119
, pp. 597-605
-
-
Mehta, C.1
Gao, P.2
Bhatt, D.L.3
Harrington, R.A.4
Skerjanec, S.5
Ware, J.H.6
-
21
-
-
84873817347
-
A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials
-
doi:10.1177/0092861512454116
-
Millen, B. A., Dmitrienko, A., Ruberg, S., Shen, L. (2012). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Information Journal. doi:10.1177/0092861512454116.
-
(2012)
Drug Information Journal
-
-
Millen, B.A.1
Dmitrienko, A.2
Ruberg, S.3
Shen, L.4
-
22
-
-
58149343878
-
K-Ras mutations are changing practice in advanced colorectal cancer
-
McNeil, C. (2008). K-Ras mutations are changing practice in advanced colorectal cancer. Journal of National Cancer Institute 100(23):1667-1669.
-
(2008)
Journal of National Cancer Institute
, vol.100
, Issue.23
, pp. 1667-1669
-
-
McNeil, C.1
-
23
-
-
0001474703
-
NIH guidelines on the inclusion of women and minorities as subjects in clinical research
-
National Institutes of Health
-
National Institutes of Health. (1994). NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register 59:14508-14513.
-
(1994)
Federal Register
, vol.59
, pp. 14508-14513
-
-
-
24
-
-
0002581436
-
When to believe a subgroup analysis
-
Guyatt, G., Rennie, D., eds. Chicago, IL: AMA Press
-
Oxman, A., Guyatt, G., Green, L., Craig, J., Walter, S., Cook, D. (2002). When to believe a subgroup analysis. In: Guyatt, G., Rennie, D., eds. Users' guides to the medical literature. A manual for evidence-based clinical practice. Chicago, IL: AMA Press, pp. 553-565.
-
(2002)
Users' Guides to the Medical Literature. A Manual for Evidence-based Clinical Practice
, pp. 553-565
-
-
Oxman, A.1
Guyatt, G.2
Green, L.3
Craig, J.4
Walter, S.5
Cook, D.6
-
25
-
-
84891793993
-
-
President signs FDA user fee bill as industry begins watching for implementation issues. Available at
-
President signs FDA user fee bill as industry begins watching for implementation issues. (2012). Sidley.com. Available at: http://www.sidley.com/ President-Signs-FDA-User- Fee-Bill-as-Industry-Begins-Watching-for- Implementation-Issues-07-09-2012
-
(2012)
Sidley.com
-
-
-
26
-
-
84861665800
-
Drotrecogin Alfa (Activated) in adult with septic shock
-
for the PROWLESS-SHOCK Study Group
-
Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J. F., Douglas, I. S., Finfer, S., Gardlund, B., Marshall, J. C., Rhodes, A., Artigas, A., Payen, D., Tenhunen, J., Al- Khalidi, H. R., Thompson, V., Janes, J., Macias, W. L., Vangerow, B., Williams, M. D., for the PROWLESS-SHOCK Study Group. (2012). Drotrecogin Alfa (Activated) in adult with septic shock. New England Journal of Medicine 366:2055-2064.
-
(2012)
New England Journal of Medicine
, vol.366
, pp. 2055-2064
-
-
Ranieri, V.M.1
Thompson, B.T.2
Barie, P.S.3
Dhainaut, J.F.4
Douglas, I.S.5
Finfer, S.6
Gardlund, B.7
Marshall, J.C.8
Rhodes, A.9
Artigas, A.10
Payen, D.11
Tenhunen, J.12
Al-Khalidi, H.R.13
Thompson, V.14
Janes, J.15
Macias, W.L.16
Vangerow, B.17
Williams, M.D.18
-
27
-
-
84864820652
-
Testing a prespecified subgroup and the intent-to-treat population
-
Rothman, M. D., Zhang, J. J., Lu, L., Fleming, T. R. (2012). Testing a prespecified subgroup and the intent-to-treat population. Drug Information Journal 46:175-179.
-
(2012)
Drug Information Journal
, vol.46
, pp. 175-179
-
-
Rothman, M.D.1
Zhang, J.J.2
Lu, L.3
Fleming, T.R.4
-
28
-
-
11844302840
-
Subgroup analysis in randomized controlled trials: Importance, indications, and interpretation
-
Rothwell, P. (2005). Subgroup analysis in randomized controlled trials: Importance, indications, and interpretation. Lancet 365:176-186.
-
(2005)
Lancet
, vol.365
, pp. 176-186
-
-
Rothwell, P.1
-
29
-
-
33646047815
-
Use of genomic signatures in therapeutics development in oncology and other diseases. Advance online publication, January 17, 2006
-
Simon, R., Wang, S. J. (2006). Use of genomic signatures in therapeutics development in oncology and other diseases. Advance online publication, January 17, 2006. Pharmacogenomics Journal 6:166-173.
-
(2006)
Pharmacogenomics Journal
, vol.6
, pp. 166-173
-
-
Simon, R.1
Wang, S.J.2
-
30
-
-
0021137170
-
The design of case-control studies: The influence of confounding and interaction effects
-
Smith, P. G., Day, N. E. (1984). The design of case-control studies: The influence of confounding and interaction effects. International Journal of Epidemiology 13:356-365.
-
(1984)
International Journal of Epidemiology
, vol.13
, pp. 356-365
-
-
Smith, P.G.1
Day, N.E.2
-
31
-
-
84859726995
-
Credibility of claims of subgroup effects in randomized controlled trials: Systematic review
-
doi: 10.1136/bmj.e1553
-
Sun, X., Briel, M., Busse, J. W., You, J. J., Akl, E. A., Mejza, F., Bala, M. M., Bassler, D., Mertz, D., Diaz-Granados, N., Vandvik, P. O., Malaga, G., Srinathan, S. K., Dahm, P., Johnston, B. C., Alonso-Coello, P., Hassouneh, B., Walter, S.D., Heels- Ansdell, D., Bhatnagar, N., Altman, D. G., Guyatt, G. H. (2012). Credibility of claims of subgroup effects in randomized controlled trials: systematic review. British Medical Journal 15:344. doi: 10.1136/bmj.e1553.
-
(2012)
British Medical Journal
, vol.15
, pp. 344
-
-
Sun, X.1
Briel, M.2
Busse, J.W.3
You, J.J.4
Akl, E.A.5
Mejza, F.6
Bala, M.M.7
Bassler, D.8
Mertz, D.9
Diaz-Granados, N.10
Vandvik, P.O.11
Malaga, G.12
Srinathan, S.K.13
Dahm, P.14
Johnston, B.C.15
Alonso-Coello, P.16
Hassouneh, B.17
Walter, S.D.18
Heels- Ansdell, D.19
Bhatnagar, N.20
Altman, D.G.21
Guyatt, G.H.22
more..
-
32
-
-
18744406319
-
Multiplicity in randomized controlled trials II: Subgroup and interim analyses
-
Schultz, K. F., Grimes, D. A. (2005). Multiplicity in randomized controlled trials II: Subgroup and interim analyses. Lancet 365:1657-1661.
-
(2005)
Lancet
, vol.365
, pp. 1657-1661
-
-
Schultz, K.F.1
Grimes, D.A.2
-
33
-
-
84891775845
-
-
Tarceva label. Available at
-
Tarceva label. (2013). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2013/021743s018lbl.pdf
-
(2013)
-
-
-
34
-
-
84891797795
-
-
Xigris label. Available at
-
Xigris label. (2007). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2007/125029s080LBL.pdf
-
(2007)
-
-
-
35
-
-
37349069551
-
Biomarker as a classifier in pharmacogenomics clinical trials: A tribute to 30th anniversary of PSI
-
Wang, S. J. (2007). Biomarker as a classifier in pharmacogenomics clinical trials: A tribute to 30th anniversary of PSI. Pharmaceutical Statistics 6:283-296.
-
(2007)
Pharmaceutical Statistics
, vol.6
, pp. 283-296
-
-
Wang . S, J.1
-
36
-
-
33645061021
-
Retrospective validation of genomic biomarkers - What are the questions, challenges and strategies for developing useful relationships to clinical outcomes - Workshop summary
-
Wang, S. J., Cohen, N., Katz, D. A., Ruano, G., Shaw, P., Spear, B. (2006). Retrospective validation of genomic biomarkers - What are the questions, challenges and strategies for developing useful relationships to clinical outcomes - Workshop summary. Pharmacogenomics Journal 6:82-88.
-
(2006)
Pharmacogenomics Journal
, vol.6
, pp. 82-88
-
-
Wang, S.J.1
Cohen, N.2
Katz, D.A.3
Ruano, G.4
Shaw, P.5
Spear, B.6
-
37
-
-
84866271129
-
Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials
-
Wang, S. J., Hung, H. M. J. (2012). Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials. Journal of Biopharmaceutical Statistics 22:879-893.
-
(2012)
Journal of Biopharmaceutical Statistics
, vol.22
, pp. 879-893
-
-
Wang, S.J.1
Hung, H.M.J.2
-
38
-
-
66349125688
-
Adaptive patient enrichment designs in therapeutic trials
-
Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51(2):358-374.
-
(2009)
Biometrical Journal
, vol.51
, Issue.2
, pp. 358-374
-
-
Wang, S.J.1
Hung, H.M.J.2
O'neill, R.T.3
-
39
-
-
34648840242
-
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
-
Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227-244.
-
(2007)
Pharmaceutical Statistics
, vol.6
, pp. 227-244
-
-
Wang, S.J.1
O'neill, R.T.2
Hung, H.M.J.3
-
40
-
-
78649960550
-
Some statistical considerations in evaluating pharmacogenomics confirmatory clinical trials
-
Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2010). Some statistical considerations in evaluating pharmacogenomics confirmatory clinical trials. Clinical Trials 7:525-536.
-
(2010)
Clinical Trials
, vol.7
, pp. 525-536
-
-
Wang, S.J.1
O'neill, R.T.2
Hung, H.M.J.3
-
41
-
-
17944379905
-
Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial
-
on belahf of the MERITHF Study Group
-
Wedel, H., DeMets, D., Deedwania, P., Fagerberg, B., Goldstein, S., Gottlieb, S., Hjalmarson, A., Kjekshus, J., Waagstein, F., Wikstrand, J., on belahf of the MERITHF Study Group. (2001). Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. American Heart Journal 142:502-511.
-
(2001)
American Heart Journal
, vol.142
, pp. 502-511
-
-
Wedel, H.1
Demets, D.2
Deedwania, P.3
Fagerberg, B.4
Goldstein, S.5
Gottlieb, S.6
Hjalmarson, A.7
Kjekshus, J.8
Waagstein, F.9
Wikstrand, J.10
-
42
-
-
0025737883
-
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Special communication
-
Yusuf, S., Wittes, J., Probstfield, J., Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Special communication. Journal of the American Medical Association 266(1):93-98.
-
(1991)
Journal of the American Medical Association
, vol.266
, Issue.1
, pp. 93-98
-
-
Yusuf, S.1
Wittes, J.2
Probstfield, J.3
Tyroler, H.A.4
|